By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Enterome, a privately held biomarker development firm, has raised €5 million ($6.6 million) in a series A round of private funding, it said Thursday.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.